BME100 f2014:Group31 L2

BME 100 Fall 2014	Home People Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3 Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6 Course Logistics For Instructors Photos Wiki Editing Help
OUR TEAM Name: Jimmy Xu Name: Andrew Liu Name: Andy Chang Name: Charles Bolton Name: Afshin Isadvesta Name: Michael Chatarachanwong LAB 2 WRITE-UP Descriptive Statistics Experiment 1 Effect of LPS Dosage on Human Inflammotin Levels 0 mg: Mean-3.834, Std. Dev-1.52301018, Count-10, Std. Error-0.48161811 5 mg: Mean-8.932, Std. Dev-1.59393155, Count-10, Std. Error-0.50404541 10 mg: Mean-61.622, Std. Dev-30.1106939, Count-10, Std. Error-9.52183745 15 mg: Mean-657.941, Std. Dev-212.942976, Count-10, Std. Error-67.3384817 Experiment 2 Effect of LPS Dosage on Rat Inflammotin Levels 0 mg: Mean-10.516, Std. Dev-2.22555162, Count-5, Std. Error-0.99529694 10 mg: Mean-11.112, Std. Dev-7.40288592, Count-5, Std. Error-3.31067123 Graphing In the first experiment tested on Humans, the conclusion can be lead that from 10 mg to 15 mg, there was a significant change of protein levels. In the first experiment tested on Rats, the conclusion can be lead that there is no significant change of LPS levels in rats corresponding to Protein intake. Experiment 1 ‎Experiment 2 Inferential Statistics Experiment 1 For the human experiment, an ANOVA test will be used, since there were four dosages that were tested, which is more than two. ANOVA: Single Factor Group: 5.23, Count: 9, Sum: 33.11, Average: 3.678888889, Variance: 2.338836111 Group: 10.72, Count: 9, Sum: 78.6, Average: 8.733333333, Variance: 2.414175 Group: 100.19, Count: 9, Sum: 516.03, Average: 57.33666667, Variance: 813.3897 Group: 793.17, Count: 9, Sum: 5786.24, Average: 642.9155556, Variance: 48472.95523 ANOVA Source of Variation Between Groups, SS: 2607705.519, df: 3, MS: 869235.173, F: 70.53891752, P-Value: 3.39557E-14, F-crit: 2.90111958 Within Groups, SS: 394328.7835, df: 32, MS: 12322.77448 Total, SS: 3002034.302, df: 35 The P-Value obtained from the ANOVA single factor test was less than .05. This means that there is a statistically significant difference between treatments. A Bonferroni Post-Hoc Test was done to verify the results, doing multiple t-tests between each dosage compared to all other dosages. Post ANOVA T-Test 0mg v 5mg 8.59631E-07 0mg v 10mg 9.94377E-06 0mg v 15mg 1.39436E-08 5mg v 10mg 3.01859E-05 5mg v 15mg 1.57101E-08 10mg v 15mg 6.4824E-08 Because there are 6 possible t-tests to be done, the p value must be adjusted by dividing by number of tests. So the relevant threshold will be .05/6, which is .00833. Based on the Post ANOVA t-tests, all p-values are less than .00833, which means that at every dosage, there was a statistically significant difference in inflammotin levels. Experiment 2 For the rat experiment, a t-test will be used, since there are two dosages being tested. Furthermore, the data is among two unrelated sets of data, so it is clear that we need to use an unpaired test. Unpaired T-Test p-value: 0.8674035 For the unpaired t-test run on the rat experiment, the p-value was determined to be 0.8674035, which is greater than .05. Therefore, there is no statistical difference between the groups. Since there are only two variables, no adjustment of the p-level is needed. Summary/Discussion Based on these results, there was a significant difference in protein levels for all the human tests as dosage increased. On the other hand, there was no significant difference within the rat experiment as dosage increased. Therefore, we concluded that as LPS dosage increases, inflammotin levels rise in humans and only on humans. In comparison, an increase in LPS levels in rats did not create a statistically significant change in the levels of the same protein.